* Tyndall Capital Partners LP reports 13.5 percent passive
stake in Onconova Therapeutics Inc, as of July 29, 2016 – SEC
filing
Source text for Eikon:
Further company coverage:
The post BRIEF-Tyndall Capital reports 13.5 percent passive stake in Onconova appeared first on NASDAQ.